STOCK TITAN

NeuroPace to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
NeuroPace, Inc. to participate in investor conferences
Positive
  • None.
Negative
  • No important business takes found

- Wells Fargo 2023 Healthcare Conference -

- Morgan Stanley 21st Annual Global Healthcare Conference -

- Lake Street Capital Markets 7th Annual Best Ideas Growth Conference -

MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming investor conferences:

  • Management will host 1x1 meetings at the Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023, in Everett, MA.
  • Joel Becker, CEO, and Rebecca Kuhn, CFO, will participate in a fireside chat discussion and host 1x1 meetings at the Morgan Stanley 21st Annual Global Healthcare Conference at 9:30 AM ET on Wednesday, September 13, 2023, in New York, NY.
  • Management will host 1x1 meetings at the Lake Street Capital Markets 7th Annual Best Ideas Growth Conference on Thursday, September 14, 2023, in New York, NY

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com


NeuroPace, Inc.

NASDAQ:NPCE

NPCE Rankings

NPCE Latest News

NPCE Stock Data

235.04M
10.70M
3.95%
80.9%
0.3%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MOUNTAIN VIEW

About NPCE

the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.